Open AccessThe Potential Clinical and Economic Value of a Human Papillomavirus Primary Screening Test That Additionally Identifies Genotypes 31, 45, 51, and 52 Individually
Author(s) -
Lindsey Asti,
Colin Hopley,
Cameron Avelis,
Sarah M. Bartsch,
Leslie E. Mueller,
Molly Domino,
Sarah N Cox,
Jeffrey C Andrews,
Samuel Randall,
Owen J. Stokes-Cawley,
Caitlin Asjes,
Bruce Y. Lee
Publication year - 2020
Publication title -
sexually transmitted diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.507
H-Index - 105
eISSN - 1537-4521
pISSN - 0148-5717
DOI - 10.1097/olq.0000000000001327
Subject(s) - genotyping , medicine , colposcopy , genotype , gynecology , cervical cancer , obstetrics , oncology , cancer , genetics , biology , gene
Although current human papillomavirus (HPV) genotype screening tests identify genotypes 16 and 18 and do not specifically identify other high-risk types, a new extended genotyping test identifies additional individual (31, 45, 51, and 52) and groups (33/58, 35/39/68, and 56/59/66) of high-risk genotypes.